Elafibranor treats Primary Biliary Cholangitis, Genfit patent
Summary
Elafibranor treats Primary Biliary Cholangitis, Genfit patent
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for the treatment of primary biliary cholangitis
Grant US12589086B2 Kind: B2 Mar 31, 2026
Assignee
Genfit
Inventors
Pascal Birman, Alice Roudot, David Magrez, Benoit Noel
Abstract
The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
CPC Classifications
A61K 31/192 A61P 1/16
Filing Date
2021-08-25
Application No.
18017591
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.